company background image
SVE logo

Synthaverse WSE:SVE Stock Report

Last Price

zł3.91

Market Cap

zł275.7m

7D

1.6%

1Y

-27.1%

Updated

27 Mar, 2024

Data

Company Financials

SVE Stock Overview

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.

SVE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health2/6
Dividends0/6

Synthaverse S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Synthaverse
Historical stock prices
Current Share Pricezł3.91
52 Week Highzł6.40
52 Week Lowzł3.55
Beta1.27
1 Month Change-0.51%
3 Month Change-8.77%
1 Year Change-27.08%
3 Year Change-74.19%
5 Year Change365.48%
Change since IPO-18.54%

Recent News & Updates

Recent updates

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

Oct 14
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

Nov 29
More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Nov 16
We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

May 02
Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

Mar 08
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Jan 29
What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 03
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Dec 07
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Shareholder Returns

SVEPL BiotechsPL Market
7D1.6%0.07%2.3%
1Y-27.1%-17.6%35.3%

Return vs Industry: SVE underperformed the Polish Biotechs industry which returned -16.5% over the past year.

Return vs Market: SVE underperformed the Polish Market which returned 35.7% over the past year.

Price Volatility

Is SVE's price volatile compared to industry and market?
SVE volatility
SVE Average Weekly Movement4.1%
Biotechs Industry Average Movement4.9%
Market Average Movement5.0%
10% most volatile stocks in PL Market9.5%
10% least volatile stocks in PL Market3.2%

Stable Share Price: SVE has not had significant price volatility in the past 3 months.

Volatility Over Time: SVE's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1944234Mieczyslaw Starkowiczhttps://www.synthaverse.pl

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma.

Synthaverse S.A. Fundamentals Summary

How do Synthaverse's earnings and revenue compare to its market cap?
SVE fundamental statistics
Market capzł275.74m
Earnings (TTM)zł3.46m
Revenue (TTM)zł52.76m

79.7x

P/E Ratio

5.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SVE income statement (TTM)
Revenuezł52.76m
Cost of Revenuezł22.21m
Gross Profitzł30.55m
Other Expenseszł27.09m
Earningszł3.46m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 10, 2024

Earnings per share (EPS)0.049
Gross Margin57.91%
Net Profit Margin6.56%
Debt/Equity Ratio49.0%

How did SVE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.